News
-
Krystal Biotech announced that it will develop injectable and inhaled versions of its KB707 gene therapy for the treatment of malignant solid tumors, including metastatic cancer. The company said that it intends to amend an… Read more . . .
-
Amneal Pharmaceuticals announced that it has submitted ANDAs for three complex generics, including a generic version of Teva’s ProAir HFA albuterol sulfate metered dose inhaler. Currently, the only listed therapeutic equivalent for ProAir HFA is… Read more . . .
-
According to Lupin, the company’s generic version of Boehringer Ingelheim’s Spiriva Handihaler tiotropium bromide DPI has been approved for the treatment of COPD by Australia’s Therapeutic Goods Administration (TGA). Lupin said that it will manufacture… Read more . . .
-
The Court of Appeals for the Federal Circuit has upheld rulings by the United States District Court for the District of Delaware in a patent infringement suit filed by United Therapeutics against Liquidia Corporation alleging that Liquidia’s… Read more . . .
-
Insilico Medicine, which claims to be “a generative artificial intelligence (AI)-driven clinical-stage drug discovery company,” said that it is “the first AI drug discovery company to venture into nebulized formulations” as the company plans to… Read more . . .
-
Lupin announced that its German subsidiary Hormosan Pharma has launched Luforbec beclometasone / formoterol MDI for the treatment of asthma and COPD in Germany. According to Lupin, the price of the MDI, which is a generic… Read more . . .
-
Altamira Therapeutics announced that Pharma Nordic will market and distribute Bentrio bentonite-based OTC nasal spray for protection against allergens in Norway as part of a deal that could potentially expand to include Sweden, Finland, and Denmark,… Read more . . .
-
The FDA has approved Padagis’s supplemental application for over-the-counter sales of the company’s generic version of Narcan naloxone nasal spray, 4 mg, for the reversal of opioid overdose. Padagis initially launched its generic in the… Read more . . .
-
Zambon said that the Phase 3 PROMIS-II trial of its CMS I-neb inhaled dry powder colistimethate sodium for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult patients with chronic P. aeruginosa lung infections failed… Read more . . .
-
Advent Therapeutics announced that the company has received a $3 million Small Business Innovation Research (SBIR) Phase 2B grant from the National Institutes of Health for continued development of the company’s inhaled vitamin A (retinol)… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland